Acute monocytic leukemia
MONDO:0007896Acute monoblastic leukemia (AML-M5), is one of the most common subtypes of acute myeloid leukemia (AML) that is either comprised of more than 80% of monoblasts (AML-M5a) or 30-80% monoblasts with (pro)monocytic differentiation (AML-M5b). AML-M5 presents with asthenia, pallor, fever, and dizziness. Specific features of AML-M5 include hyperleukocytosis, propensity for extramedullary infiltrates, coagulation abnormalities including disseminated intravascular coagulation and neurological disorders. Leukemia cutis and gingival infiltration can also be seen. A characteristic translocation observed in AML-M5 is t(9;11).
Also known as: monocytic leukaemia, monocytic leukemia, AML M5, acute monoblastic leukaemia and acute monocytic leukaemia, acute monocytic leukaemia (FAB M5B), acute monocytic leukaemia (FAB M5b), acute monocytic leukemia, acute monocytic leukemia (FAB M5B)
3094 clinical trials for this condition and its sub-types, 20 tagged with Acute monocytic leukemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Acute monocytic leukemia
-
Adult acute monocytic leukemia 4 trials
-
Aleukemic monocytic leukemia cutis 0 trials
-
Subacute monocytic leukemia 0 trials
-
Old drug, new hope: enasidenib may ease anemia in blood cancer patients
Disease control CompletedThis early-phase trial tested the drug enasidenib in 17 people with low-risk myelodysplastic syndrome or a related leukemia who had anemia and did not have a specific gene mutation. The goal was to see if the drug could safely improve red blood cell counts and reduce the need for…
Phase 1/2 • Sponsor: Tian Yi Zhang • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Platelet-Boosting drug speed recovery for older leukemia patients?
Disease control CompletedThis phase II trial investigates whether eltrombopag, a drug that stimulates platelet production, can help older adults with acute myeloid leukemia (AML) recover their platelet counts faster after initial chemotherapy. Older patients often experience slow platelet recovery, which…
Phase 2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Could a targeted drug keep AML in check?
Disease control CompletedThis phase III trial tests whether the drug tipifarnib can prevent acute myeloid leukemia (AML) from coming back in patients who are already in remission. Participants include adults over 60 in first remission, those in second or later remission, or those who achieved remission a…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New hope for frail AML patients: stronger chemo regimens tested
Disease control CompletedThis study tests whether giving full-strength chemotherapy (either CPX-351 or a combination called CLAG-M) can help medically less-fit adults with acute myeloid leukemia live longer and achieve remission. About 60 participants will receive one of the two treatments. The goal is t…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
High-Dose therapy plus stem cell transplant shows promise for AML patients
Disease control CompletedThis phase 2 trial tested a treatment for adults with acute myeloid leukemia (AML) in first remission. Patients received high-dose chemotherapy and radiation to kill cancer cells, followed by an autologous stem cell transplant (using their own stem cells) to restore blood cell pr…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC